
News|Articles|February 1, 2011
FDA Pipeline Preview, February 2011 (Afrezza, Nuvigil, Opana ER, Liprotamase, Erwinaze, Telaprevir, SNS01-T, XL184, QLT091001, Fidaxomicin)
Recent FDA action (through, January 2011) related to Afrezza, Nuvigil, Opana ER, Liprotamase, Erwinaze, Telaprevir, SNS01-T, XL184, QLT091001, Fidaxomicin.
Advertisement
Complete response
Not recommended for approval
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
2
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
3
ACIP votes to end universal birth-dose for hepatitis B vaccine with updated guidance for parents and doctors
4
New test may solve the specificity and false-positive problems of the PSA test for prostate cancer
5





















































